MedPath

Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder

Phase 1
Conditions
Binge Eating Disorder
MedDRA version: 24.0Level: PTClassification code: 10004716Term: Binge eating Class: 100000004873
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Registration Number
CTIS2024-515475-35-00
Lead Sponsor
niversitaetsmedizin Goettingen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Patients with BED according to DSM-5, Male or female patients aged between 18 and 40 (the upper age limit was chosen to minimise potential confounding effects by hormonal changes related to menopause), Written informed consent obtained according to international guidelines and local laws, Ability to understand the nature of the trial and the trial related procedures and to comply with them.

Exclusion Criteria

systemic (i.v. or oral) glucocorticoid treatment within the last 3 months, known pheochromocytoma, Simultaneous participation in another interventional trial, Pregnant or breastfeeding females, current diagnosis of a psychotic, bipolar, or substance use disorder, severe somatic illness (e.g. cancer, cardiovascular disease, instable diabetes mellitus; blood pressure = 160/100 mmHg at rest and/or current treatment of hypertensive crisis within last 6 months), current or planned use of psychotropic medication (during the period of the study), current or planned psychotherapy (during the period of the study), known hypersensitivity to hydrocortisone, known hereditary galactose intolerance, known lactase deficiency, known glucose-galactose malabsorption

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath